Share This Article:

Preference of Dogs between Two Commercially Available Oral Formulations of Ectoparasiticide Containing Isoxazolines, Afoxolaner or Fluralaner

Abstract Full-Text HTML XML Download Download as PDF (Size:875KB) PP. 25-29
DOI: 10.4236/ojvm.2015.52004    3,085 Downloads   4,523 Views   Citations

ABSTRACT

Because of their convenience, oral dosage forms are an emerging trend in companion animal formulations. Ectoparasiticides represent a significant proportion of the treatments administered to pets, and recently oral formulations have been commercialized. They have to demonstrate high palatability to ensure that they are voluntarily accepted by the animal especially because they are repeatedly offered medications. The present study aimed to compare the dog’s preference between two commercially available oral ectoparasiticide formulations containing either afoxolaner (NexGard®, Merial) or fluralaner (Bravecto®, MSD Animal Health). In two separate experiments, 225 individual dogs (115 and 110 respectively) were offered a choice of afoxolaner or fluralaner chewable tablets. The 225 dogs were given an opportunity to smell both products, and then the products were simultaneously offered to each dog by hand for 4 consecutive days with products offered from alternate hands on each day. Individual consumption and related behaviors were recorded. The same individual offered the products to the dogs throughout each study. The total number of chewable tablets for each formulation was recorded and preference was evaluated as the consumption of a given formulation during more days. A total amount of 797 tablets were consumed by the 225 dogs during the 4 days of the studies. A total of 573 (71.9%) afoxolaner chews and 224 (28.1%) fluralaner chews were consumed voluntarily. The overall consumption ratio was 2.56 to 1 for NexGard® to Bravecto®, with significantly (p < 0.0001) more dogs consuming NexGard® than Bravecto® on each day. As for dogs demonstrating a preference over the entire test period; 83% of the dogs tested preferred NexGard® to Bravecto®, resulting in a preference ratio of 5 to 1 for afoxolaner formulation versus fluralaner formulation. This study demonstrated that when dogs were offered a choice between the two ectoparasiticide products, a significant preference for NexGard® was observed.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Halos, L. , Carithers, D. , Solanki, R. , Stanford, H. and Gross, S. (2015) Preference of Dogs between Two Commercially Available Oral Formulations of Ectoparasiticide Containing Isoxazolines, Afoxolaner or Fluralaner. Open Journal of Veterinary Medicine, 5, 25-29. doi: 10.4236/ojvm.2015.52004.

References

[1] Petry, G., Fourie, J. and Wolken, S. (2014) Comparison of the Palatability of a New Flavoured Drontal® Plus Tablet (Drontal® Plus Treat 10 kg) and Milbemax® Chewable Tablets When Presented to Privately Owned Dogs. Open Journal of Veterinary Medicine, 4, 163-169. http://dx.doi.org/10.4236/ojvm.2014.48018
[2] Thombre, A.G. (2004) Oral Delivery of Medications to Companion Animals: Palatability Considerations. Advanced Drug Delivery Reviews, 56, 1399-1413. http://dx.doi.org/10.1016/j.addr.2004.02.012
[3] Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (2014) Guideline on the Demonstration of Palatability of Veterinary Medicinal Products.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/11/WC500134876.pdf
[4] Beugnet, F. and Franc, M. (2012) Insecticide and Acaricide Molecules and/or Combinations to Prevent Pet Infestation by Ectoparasites. Trends in Parasitology, 28, 267-279
http://dx.doi.org/10.1016/j.pt.2012.04.004
[5] Shoop, W.L., Hartline, E.J., Gould, B.R., Waddell, M.E., McDowell, R.G., Kinney, J.B., Lahm, G.P., Long, J.K., Xu, M., Wagerle, T., Jones, G.S., Dietrich, R.F., Cordova, D., Schroeder, M.E., Rhoades, D.F., Benner, E.A. and Confalone, P.N. (2014) Discovery and Mode of Action of Afoxolaner, a New Isoxazoline Parasiticide for Dogs. Veterinary Parasitology, 201, 179-189. http://dx.doi.org/10.1016/j.vetpar.2014.02.020
[6] European Medicines Agency (2014) Nexgard Summary of Product Characteristics.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002729/WC500164067.pdf
[7] Walther, F.M., Allan, M.J., Roepke, R.K. and Nuernberger, M.C. (2014) Safety of Fluralaner Chewable Tablets (Bravecto), a Novel Systemic Antiparasitic Drug, in Dogs after Oral Administration. Parasites and Vectors, 7, 481.
[8] European Medicines Agency (2014) Bravecto Summary of Product Characteristics.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002526/WC500163859.pdf
[9] European Medicines Agency (2014) NexGard Chewable Tablets for Dogs. Registration File for Marketing Authorisation. (EU/2/13/159) Market Authorization granted on 11.2.2014.
[10] Araujo, J.A., Studzinski, C.M., Larson, B.T. and Milgram, N.W. (2004) Comparison of the Cognitive Palatability Assessment Protocol and the Two-Pan Test for Use in Assessing Palatability of Two Similar Foods in Dogs. American Journal of Veterinary Research, 65, 1490-1496.
http://dx.doi.org/10.2460/ajvr.2004.65.1490
[11] Guaguère, E. and Beugnet, F. (2008) Parasitic Skin Conditions. In: Guaguère, E., Prélaud, P. and Craig, M., Eds, A Practical Guide to Canine Dermatology, Kalianxis, Paris, 179-226.
[12] Berrada, Z.L. and Telford III, S.R. (2009) Burden of Tick-Borne Infections on American Companion Animals. Topics in Companion Animal Medicine, 24, 175-181. http://dx.doi.org/10.1053/j.tcam.2009.06.005
[13] Coles, T.B. and Dryden, M.W. (2014) Insecticide/Acaricide Resistance in Fleas and Ticks Infesting Dogs and Cats. Parasites and Vectors, 7, 8. http://dx.doi.org/10.1186/1756-3305-7-8
[14] Halos, L., Beugnet, F., Cardoso, L., Farkas, R., Franc, M., Guillot, J., Pfister, K. and Wall, R. (2014) Flea Control Failure? Myths and Realities. Trends in Parasitology, 30, 228-233.
http://dx.doi.org/10.1016/j.pt.2014.02.007

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.